Syndicate content

ReNeuron Signs Collaboration to Produce Human Neural Stem Cell (hNSC)-Derived Exosomes & to Load Them with Novel Gene-Silencing Therapeutics from Un-Named Collaborating US Biotech Company; ReNeuron Will Provide Loaded Exosomes to Collaborator

On June 25, 2020, ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announced that it has signed a new research evaluation agreement with a major US biotechnology company in connection with the use of the ReNeuron’s proprietary exosomes for the delivery of novel gene-silencing therapeutics. This latest research collaboration will focus on the use of ReNeuron’s human neural stem cell (hNSC)-derived exosomes for the delivery of the US biotechnology company’s neuroscience therapeutic candidates. ReNeuron will be responsible for manufacturing exosomes and then loading them with the gene-silencing sequences after which the US biotechnology company will evaluate the loaded exosomes. Assuming positive results, the parties will jointly own the novel therapeutic candidate created for future development. The research evaluation agreement is in line with ReNeuron’s strategy of partnering its exosome technology as a novel delivery vehicle. This new agreement follows an exosome research collaboration with a major pharmaceutical company announced by ReNeuron on April 7, 2020 (http://www.reneuron.com/wp-content/uploads/RENE-Exosome-research-collabo...), reflecting the increasing level of industry interest in exosomes. ReNeuron has developed exosomes derived from hNSCs that have a natural ability to cross the blood-brain barrier and can thus be used to deliver therapeutics for diseases of the brain. The hNSC-derived exosomes can be produced through a fully-qualified, xeno-free, scalable process and the clinical-grade hNSC source cell-line ensures consistent exosome product. The hNSC exosomes can be loaded with a diverse range of potential therapeutics, such as siRNA/mRNA/miRNA, CRISPR/Cas9, antibodies, peptides, and small molecules. Commenting on the agreement, Olav Hellebø, Chief Executive Officer of ReNeuron, said: “We are delighted to be collaborating with this major US biotechnology company in the discovery and development of novel gene-silencing-based therapeutics. This latest exosome collaboration follows our strategy of collaborating and out-licensing our proprietary exosome technology as a novel delivery vector and underlines the potential commercial value of these proprietary nanoparticles.”

EXOSOMES/EVS WILL BE SUBJECT OF UPCOMING ISEV VIRTUAL MEETING JULY 20-22

With respect to exosomes/extracellular vesicles (EVs), the International Society for Extracellular Vesicles (ISEV) Annual Meeting (ISEV 2020), including exosomes, is now VIRTUAL (July 20-22); with over 600 discussions (plenary addresses, panel sessions, oral abstract talks, poster chats, & educational sessions). The ISEV 2020 program can viewed here (https://www.isev.org/mpage/2020Home) and registration can be done here (https://www.isev.org/mpage/2020Registration). As eminent Yale professor Philip Askenase, MD, has said, “Exosomes are a sensational biological discovery and they seem to be involved in nearly all biological and clinical processes.” You may attend the virtual ISEV 2020 meeting to learn more about these fascinating, and potentially immensely important, tiny particles. All meeting materials, including all presentations, will be available to registrants for 60 days after the live portion of the meeting has ended.

[ReNeuron Press Release] [ReNeuron] [ISEV 2020 Virtual Annual Meeting] [ISEV 2020 Virtual Annual Meeting Registration]